The biopsy result came back positive. Melanoma, stage III. But what the oncologist didn't mention — what the patient never heard — was that buried inside those tumor cells was a protein the immune system had never learned to recognize. A protein that, under normal circumstances, is expressed only in the testes, safely hidden behind the blood-testis barrier where immune surveillance never reaches. Now that same protein was being manufactured by cancer cells and displayed on their surface, waving a molecular flag that an educated immune system could theoretically destroy.
That protein is NY-ESO-1. And the nine-amino-acid fragment that unlocks the immune system's ability to see it — NY-ESO-1 157-165 — has become one of the most studied epitope peptides in cancer immunology. It's not a drug. It's a research tool, a vaccine component, an adoptive cell therapy anchor, and a window into how the immune system can be taught to hunt and kill tumors that have been hiding in plain sight for years.
This guide covers everything: the discovery, the biochemistry, the mechanism by which this peptide turns naïve T-cells into tumor hunters, the clinical trial data, and what researchers need to know before sourcing it.
---
The Discovery: Finding an Antigen Where None Should Exist
The year was 1997. Yao-Tseng Chen and his colleagues at Memorial Sloan Kettering Cancer Center were using a technique called SEREX (Serological Analysis of Recombinant cDNA Expression Libraries) to screen for proteins that triggered antibody responses in cancer patients. The idea was simple but powerful: if a cancer patient's own immune system had raised antibodies against something, that something was probably tumor-associated and immunogenic.
They found a strongly immunogenic antigen in an esophageal cancer patient. When they sequenced it, something strange emerged. The gene — which they named NY-ESO-1 (New York Esophageal Squamous Cell Carcinoma 1) — was expressed in the testes of healthy men. And almost nowhere else. Not in liver, not in lung, not in brain. Just testes, and occasionally placenta.
Except in cancer cells. There, it was back with a vengeance.
This made NY-ESO-1 what immunologists call a cancer-testis antigen (CTA). The testes are immunologically privileged — they express minimal MHC class I molecules and are physically separated from circulating lymphocytes. So when a fetal protein that's normally confined to that privileged sanctuary starts getting expressed in tumor cells that *do* have MHC class I, the immune system encounters it as foreign. Not quite foreign enough to always mount an attack spontaneously, but foreign enough that it can be targeted with the right immunological nudge.
NY-ESO-1 is encoded by the CTAG1B gene on the X chromosome. The protein itself is 180 amino acids long, with a molecular weight of approximately 22 kDa. Its function in spermatogenesis remains incompletely understood, though evidence points to roles in chromatin remodeling during germ cell development.
The specific nine-amino-acid sequence that would become the cornerstone of cancer immunotherapy research — SLLMWITQC, spanning positions 157 to 165 — was identified in the late 1990s by multiple groups independently screening for HLA-A*0201-restricted T-cell epitopes. This sequence binds with exceptionally high affinity to the HLA-A*0201 molecule, the most common HLA allele in Western populations, present in roughly 40-50% of Caucasians and significant proportions of most other ethnic groups.
The fact that the most immunogenic epitope happened to be restricted to the most common HLA type wasn't luck — it was the reason NY-ESO-1 157-165 became a dominant tool in the field. You could design a vaccine or T-cell therapy, and immediately have a large, genetically accessible patient population to test it in.
---
Chemical Identity: Nine Amino Acids, Maximum Impact
NY-ESO-1 157-165 has the amino acid sequence SLLMWITQC (Ser-Leu-Leu-Met-Trp-Ile-Thr-Gln-Cys). At just nine residues, it sits at the minimum length for a standard MHC class I epitope — class I grooves typically accommodate peptides of 8-11 amino acids.
Key structural properties:
Molecular weight: ~1,052 Da (free acid form)
Sequence: Ser-Leu-Leu-Met-Trp-Ile-Thr-Gln-Cys (SLLMWITQC)
HLA restriction: Primarily HLA-A*0201 (also binds HLA-A*0205 and HLA-A*0206 with lower affinity)
Anchor residues: Leucine at position 2 (P2) and cysteine at position 9 (P9-Ω) — these are the key contact points that lock the peptide into the HLA groove
Solubility: Moderately hydrophobic due to the Leu-Leu-Met-Trp core; typically solubilized in DMSO then diluted in aqueous buffer
Stability: The cysteine at position 9 can form disulfide bonds; researchers typically use it in reduced form (with DTT or TCEP) or as the oxidized dimer for different applications
CAS Number: Not universally assigned; supplied by research vendors with sequence verification via HPLC and mass spectrometry
The hydrophobic core — LLMWI — is what drives the exceptionally tight binding to HLA-A*0201. Tryptophan at position 5 makes a particularly important van der Waals contact with the HLA groove. This creates a binding affinity (IC50) in the range of 1-10 nM for HLA-A*0201, placing it among the highest-affinity natural epitopes known.
For researchers working with the peptide, the free cysteine at P9 deserves attention. In solution, it can undergo oxidation to form a disulfide-linked dimer (SLLMWITQC-SS-CSLLMWITQC). Several studies have shown the dimer has altered immunogenicity compared to the monomer — sometimes enhanced, sometimes reduced depending on the application. Always verify your preparation's oxidation state with mass spectrometry before use.
A modified analog, NY-ESO-1 157-165 C→A (cysteine replaced with alanine at position 9), is used in some research contexts to eliminate the oxidation variable. It retains HLA-A*0201 binding but has slightly different TCR contact properties.
---
Mechanism of Action
Primary Mechanism: HLA-A*0201 Presentation and CD8+ T-Cell Activation
Understanding how NY-ESO-1 157-165 works requires understanding the antigen presentation pathway that makes cancer immunotherapy possible.
Inside a tumor cell expressing NY-ESO-1, the full-length protein is continuously synthesized and degraded by the proteasome — the cell's protein recycling machinery. During degradation, the proteasome generates peptide fragments of varying lengths. Some of these fragments, including the 157-165 sequence, enter the endoplasmic reticulum via the TAP (Transporter associated with Antigen Processing) complex. There, they encounter MHC class I molecules (in HLA-A*0201 patients, the HLA-A*0201 molecule specifically) and bind into the peptide-binding groove.
The resulting peptide-MHC (pMHC) complex travels to the cell surface and is displayed for inspection. This is the molecular equivalent of the tumor cell holding up a sign that reads: *I'm making NY-ESO-1.*
Now the immune system side: CD8+ cytotoxic T lymphocytes (CTLs) carry T-cell receptors (TCRs) on their surface. When a TCR encounters an HLA-A*0201/NY-ESO-1 157-165 complex with sufficient affinity, it triggers a signaling cascade:
1. TCR-pMHC engagement → activation of ZAP-70 kinase
2. ZAP-70 phosphorylates LAT (Linker for Activation of T cells)
3. LAT recruits PLCγ1, which generates IP3 and DAG
4. IP3 triggers calcium release → NFAT translocation to nucleus
5. DAG activates PKCθ → NF-κB activation
6. Combined transcriptional activation drives IL-2 production (T-cell proliferation signal) and upregulation of granzyme B, perforin, and IFN-γ
The result is a clonally expanded population of NY-ESO-1-specific CTLs — T-cells that will hunt down and destroy any cell displaying the HLA-A*0201/NY-ESO-1 157-165 complex. This means any tumor cell expressing NY-ESO-1 becomes a target.
In the vaccine context, researchers administer the peptide along with adjuvants (typically Montanide ISA-51, CpG oligonucleotides, or poly-ICLC) to dendritic cells in the skin and draining lymph nodes. These dendritic cells process and present the peptide, then migrate to lymph nodes where they prime naïve CD8+ T-cells. The adjuvant provides the danger signal (often a TLR agonist) that converts tolerance into immunity.
Secondary Pathways: CD4+ T-Cell Help and Antibody Responses
NY-ESO-1 157-165 is primarily an MHC class I epitope, activating CD8+ T-cells. But the full immunological picture is more complex.
The same NY-ESO-1 protein contains separate MHC class II epitopes — notably the NY-ESO-1 119-143 long peptide — that activate CD4+ helper T-cells. When researchers administer overlapping or long peptides that span both class I and class II epitopes, they generate simultaneous CD4+ and CD8+ responses. This matters enormously because:
CD4+ T-cells: provide cytokine support (IL-2, IFN-γ, TNF-α) that sustains CD8+ T-cell expansion and prevents exhaustion
CD4+ help is required for optimal T-cell memory formation
CD4+ cells can independently target tumors expressing NY-ESO-1 on MHC class II (which some tumor cells upregulate under IFN-γ stimulation)
NY-ESO-1 also uniquely stimulates spontaneous humoral immunity in cancer patients. Approximately 10-15% of patients with NY-ESO-1-expressing tumors develop natural anti-NY-ESO-1 antibodies without any vaccination. These antibodies are detectable by ELISA and have become a biomarker for tumor NY-ESO-1 expression — researchers now screen for them to identify patients most likely to respond to NY-ESO-1-targeted therapies.
In adoptive cell therapy (ACT) research, the 157-165 epitope serves a different mechanistic role. Researchers use NY-ESO-1 157-165/HLA-A*0201 tetramers — soluble, fluorescently labeled pMHC complexes — to isolate, identify, and expand NY-ESO-1-specific T-cells ex vivo. These tetramers bind with sufficient avidity to stain and sort T-cells by flow cytometry without activating them, allowing precision cell engineering before infusion.
Systemic vs. Local Effects: Administration Route Matters
How and where NY-ESO-1 157-165 is delivered dramatically shapes the immune response generated.
Subcutaneous injection (the most common route in vaccine trials) delivers the peptide to dermal and subcutaneous dendritic cells. With oil-based adjuvants like Montanide ISA-51, a depot effect forms — slow antigen release over days creates prolonged DC stimulation. This generates high-magnitude CTL responses but can sometimes cause granulomas at injection sites.
Intradermal injection targets Langerhans cells and dermal DCs directly, potentially generating stronger CD8+ responses per microgram of peptide. Several trials have compared routes head-to-head; intradermal delivery with appropriate adjuvants tends to generate superior tetramer-positive CD8+ T-cell frequencies.
Nanoparticle encapsulation is an emerging delivery strategy. Loading NY-ESO-1 157-165 into lipid nanoparticles or PLGA microspheres improves uptake by DCs, protects the peptide from serum proteases, and allows co-delivery with adjuvants directly into the same DC. Early preclinical data shows 3-5x higher tetramer-positive T-cell frequencies compared to free peptide plus adjuvant.
Ex vivo pulsing — where the peptide is used to load patient-derived or allogeneic DCs in culture before reinfusion — bypasses the in vivo delivery problem entirely. The DCs are loaded under controlled conditions (typically 1-10 μg/mL peptide for 2-4 hours), matured with TLR agonists, and infused into patients where they home to lymph nodes and prime T-cells.
---
The Evidence Base: Clinical and Preclinical Research
Melanoma Vaccine Trials
Melanoma was the first tumor type where NY-ESO-1 157-165 vaccine research showed clear immunological proof-of-concept. NY-ESO-1 is expressed in 20-30% of melanoma cases, making it a realistic target for a significant patient subset.
In a landmark 2004 study by Jäger et al. published in *PNAS*, patients with NY-ESO-1-expressing melanoma received vaccination with NY-ESO-1 157-165 peptide combined with Montanide ISA-51 adjuvant. Tetramer-positive CD8+ T-cells were detected in peripheral blood in 5 of 9 evaluable patients, reaching frequencies of up to 1-3% of circulating CD8+ T-cells — remarkably high for a spontaneous antigen. Integrated antibody and T-cell responses were associated with tumor regression in 2 patients.
A 2009 study from the Ludwig Cancer Research group (Karbach et al., *Clinical Cancer Research*) tested NY-ESO-1 157-165 with the TLR9 agonist CpG-7909 as adjuvant in 12 melanoma patients. CpG significantly enhanced CD8+ T-cell priming compared to Montanide alone, with plasmacytoid dendritic cell activation identified as the key amplifying step. Tetramer-positive frequencies reached 0.5-2% in 8/12 patients.
The ISCOMATRIX adjuvant studies from Peter MacCallum Cancer Centre (Maraskovsky et al., *Clinical Cancer Research*, 2004) used a formulation combining full-length NY-ESO-1 protein with ISCOMATRIX particles, generating both CD8+ responses to the 157-165 epitope and CD4+ responses to class II epitopes simultaneously. This remains one of the best-characterized combination approaches.
Key finding: In the ISCOMATRIX trial, 22/46 patients developed detectable NY-ESO-1-specific CD8+ T-cell responses, and patients with integrated humoral + cellular immunity showed significantly longer progression-free survival (median 18 vs. 6 months).
Adoptive T-Cell Therapy
The most dramatic clinical results with NY-ESO-1 157-165 have come not from vaccines but from adoptive cell therapy — specifically from the engineered TCR-T cell work pioneered at the National Cancer Institute and Memorial Sloan Kettering.
In a 2011 *Journal of Clinical Oncology* study by Robbins et al., 11 patients with metastatic synovial cell sarcoma or melanoma received infusion of autologous T-cells genetically engineered to express a high-affinity NY-ESO-1-specific TCR (the 1G4 TCR). The 1G4 TCR recognizes the 157-165 epitope with a KD of approximately 26 nM — orders of magnitude higher affinity than natural TCRs, which typically have KD values of 1-100 μM. 4 of 6 synovial sarcoma patients achieved objective responses, including 1 complete response. 5 of 11 melanoma patients responded.
This study was transformative. Synovial sarcoma is a soft tissue cancer with almost no effective systemic therapies; a 67% response rate in a heavily pre-treated population was extraordinary. And the mechanism was clear: the 157-165 peptide, presented by HLA-A*0201 on tumor cells, was the molecular target that the engineered TCR recognized.
A subsequent 2015 study (Robbins et al., *Clinical Cancer Research*) extended the cohort to 18 sarcoma patients with the optimized 1G4 TCR, achieving an objective response rate of 61% with 2 complete responses and median progression-free survival of 7.3 months — remarkable for this tumor type.
The NY-ESO-1 CAR-T approach uses a different strategy: engineering T-cells with chimeric antigen receptors that include a single-chain variable fragment (scFv) derived from anti-NY-ESO-1 antibodies. Unlike TCR-T cells, CAR-T cells don't require HLA matching. Phase I trials are ongoing, but early data suggests they can achieve tumor control in NY-ESO-1-positive myeloma and sarcoma.
Lung Cancer and Other Solid Tumors
Non-small cell lung cancer (NSCLC) expresses NY-ESO-1 in approximately 15-30% of cases, with higher expression in squamous cell subtypes. The LUD00-009 trial (Gnjatic et al., *PNAS*, 2006) examined NY-ESO-1 immunity in NSCLC patients receiving peptide vaccination and found that NY-ESO-1 157-165-specific CTL responses were detectable in the majority of vaccinated HLA-A*0201+ patients, though clinical responses were modest as monotherapy.
The combination with checkpoint blockade is where things get interesting. When NY-ESO-1 157-165-specific T-cells are primed by vaccination but then encounter PD-L1-expressing tumors, the T-cells become exhausted. Anti-PD-1 antibodies (pembrolizumab, nivolumab) can rescue these exhausted but antigen-specific T-cells. A 2018 study in *Nature Medicine* (Ott et al.) showed that neoantigen peptide vaccination combined with pembrolizumab in melanoma patients generated durable T-cell responses — and the NY-ESO-1 157-165 epitope was among the shared antigens contributing to response in NY-ESO-1-positive patients.
Ovarian cancer has one of the highest NY-ESO-1 expression rates: 30-40% of cases, increasing to 70-80% in advanced, chemotherapy-resistant disease. The NCI ovarian cancer TCR-T trial (Adoptive Immunotherapy with NY-ESO-1-Specific TCR-Engineered T Cells, NCT01567891) enrolled HLA-A*0201+ patients with NY-ESO-1-expressing ovarian cancer and demonstrated feasibility and early signals of efficacy, with 2/11 patients achieving partial responses.
Comparison Table: Key NY-ESO-1 157-165 Studies
| Study | Model | Approach | Dose/Protocol | Key Finding |
|---|---|---|---|---|
| Jäger et al., PNAS 2004 | Melanoma patients (n=9) | Peptide vaccine + Montanide | 200 μg peptide SC q2w | CTL responses in 5/9; 2 tumor regressions |
| Karbach et al., CCR 2009 | Melanoma patients (n=12) | Peptide + CpG-7909 | 1 mg peptide + 2.5 mg CpG ID | Tetramer+ CD8+ in 8/12; pDC activation key |
| Maraskovsky et al., CCR 2004 | Melanoma/various (n=46) | Full protein + ISCOMATRIX | 30 μg protein + ISCOM SC | 22/46 CTL responses; survival benefit |
| Robbins et al., JCO 2011 | Sarcoma/melanoma (n=11) | 1G4 TCR-T cells | 2×10^10 cells IV | 67% ORR sarcoma; 45% ORR melanoma |
| Robbins et al., CCR 2015 | Synovial sarcoma (n=18) | Optimized 1G4 TCR-T | 2×10^10 cells IV | 61% ORR; 2 CR; mPFS 7.3 months |
| Ott et al., Nature Med 2018 | Melanoma (n=6) | Neoantigen vax + pembro | Personalized peptide pool | Durable T-cell responses; NY-ESO-1 contributor |
---
Complete Research Protocol Guide
NY-ESO-1 157-165 is a research-use-only peptide. The following protocols reflect how it is used in preclinical and clinical research settings. This is not medical advice, and this peptide is not approved for human therapeutic use outside of clinical trials.
In Vitro T-Cell Stimulation Protocols
Tetramer Staining (Flow Cytometry)
Peptide concentration: Not directly applicable (tetramers are purchased pre-loaded, typically as HLA-A*0201/SLLMWITQC PE or APC-conjugated tetramers)
Working concentration: 1-5 μg/mL tetramer in PBS + 2% FBS
Incubation: 20-30 minutes at room temperature, protected from light
Application: Identifies NY-ESO-1-specific CD8+ T-cells in peripheral blood, tumor-infiltrating lymphocyte (TIL) preparations, or TCR-engineered cell products
Peptide-Driven T-Cell Expansion (ELISpot/ICS)
Stimulation concentration: 1-10 μg/mL in complete RPMI
Duration: 18-36 hours for IFN-γ ELISpot; 6 hours with Brefeldin A for intracellular cytokine staining
Cell density: 2×10^5 PBMCs per well (ELISpot); 1×10^6/mL (ICS)
Controls: Irrelevant HLA-A*0201-restricted peptide (e.g., HIV gag 77-85 SLYNTVATL) as negative; PMA/ionomycin as positive
DC Loading for T-Cell Priming Assays
Peptide concentration: 1-10 μg/mL added to DCs for 2-4 hours
DC maturation: Add LPS (100 ng/mL) or poly-ICLC (1 μg/mL) simultaneously
Co-culture ratio: 1 DC : 10 T-cells
Readout: After 7-14 days expansion, tetramer staining + IFN-γ ELISpot
In Vivo Murine Vaccine Models (HLA-A*0201 Transgenic Mice)
Standard Vaccination Protocol
Mouse strain: HLA-A*0201/Kb transgenic (HHD mice)
Peptide dose: 50-100 μg/mouse in 100 μL total volume
Adjuvant: Incomplete Freund's adjuvant (IFA/Montanide) 1:1 emulsion, OR CpG ODN (50 μg) + Montanide
Route: Subcutaneous, base of tail or flank
Schedule: Prime on day 0, boost on day 14
Readout: Tetramer staining of splenocytes day 21; IFN-γ ELISpot
Tumor Challenge Protocol
Tumor model: NY-ESO-1-transfected B16 melanoma or MC38 colon carcinoma cells
Challenge: 5×10^5 cells SC on day 21 post-prime
Endpoints: Tumor volume (twice weekly), survival, tumor-infiltrating lymphocyte analysis
Clinical Trial Reference Doses
| Protocol Type | Peptide Dose | Adjuvant | Route | Schedule |
|---|---|---|---|---|
| Peptide vaccine (melanoma) | 100-500 μg | Montanide ISA-51 | SC | q2-4 weeks |
| Peptide vaccine (lung) | 1 mg | CpG-7909 | ID | q3 weeks |
| DC loading (ex vivo) | 1-10 μg/mL | TLR maturation cocktail | IV infusion | q4 weeks |
| TCR-T cell therapy | 2×10^9 – 2×10^10 cells | Preceded by lymphodepletion | IV | Single infusion |
| Long peptide (30mer) | 400 μg | Montanide + IFA | SC | q3 weeks |
Reconstitution and Storage
Reconstitution:
1. Allow lyophilized peptide to equilibrate to room temperature (30 minutes) before opening
2. Add 100% DMSO first: dissolve at 10-20 mg/mL to create a stock solution
3. Dilute to working concentration with PBS, RPMI, or appropriate buffer (keep DMSO < 0.1% final concentration for cell-based assays)
4. For cysteine-containing peptide: add 1 mM TCEP or 1 mM DTT to prevent dimerization if using monomer form
5. Vortex gently; do not sonicate (can cause aggregation)
Storage:
Lyophilized: -20°C, desiccated, up to 2 years
DMSO stock solution: -80°C in single-use aliquots; avoid freeze-thaw cycles
Working solution: Use within 24 hours; do not store in aqueous form
Never store in aqueous buffer at room temperature: — the methionine at position 4 is susceptible to oxidation
---
Stacking Strategies: Combining NY-ESO-1 157-165 with Complementary Immunological Tools
Protocol 1: Peptide Vaccine + Checkpoint Blockade
The rationale: NY-ESO-1 157-165 vaccination primes tumor-specific CTLs, but tumors often express PD-L1 which binds PD-1 on T-cells and induces exhaustion. Anti-PD-1/PD-L1 antibodies prevent this exhaustion signal, allowing vaccine-primed T-cells to maintain effector function.
Preclinical protocol (HHD mice):
Day 0: Prime with NY-ESO-1 157-165 (100 μg) + CpG (50 μg) in Montanide
Day 14: Boost with same formulation
Days 14-35: Anti-PD-1 antibody (200 μg/mouse) IP every 3 days
Day 21: Tumor challenge with NY-ESO-1+ tumor cells
Expected enhancement: 3-5x increase in tetramer-positive TILs vs. vaccine alone; 40-60% tumor reduction vs. 15-20% with vaccine alone in published models
Clinical reference (Ott et al., Nature Med 2018):
Peptide pool (shared + neoantigen) + pembrolizumab 200 mg q3w
Outcome: 4/6 patients with complete metabolic response at 1 year
Protocol 2: Long Peptide + CD4+ Helper Epitopes
Short peptides (9-mers) are efficiently loaded onto HLA-A*0201 but require exogenous cross-presentation. Overlapping long peptides (30-50mers) spanning both the class I epitope (157-165) and adjacent class II epitopes generate integrated CD4+/CD8+ responses.
Formulation: NY-ESO-1 119-143 long peptide (25-mer, includes class II epitopes) + NY-ESO-1 157-165 short peptide combined in ISA-51 emulsion
Dose: 400 μg long peptide + 200 μg short peptide per injection
Adjuvant: Montanide ISA-51 (1:1 v/v) + poly-ICLC (0.5 mg IM separately)
Schedule: Monthly for 3 cycles
Expected outcome: Integrated CD4+/CD8+ response in 60-80% of HLA-A*0201+ patients; antibody responses in 40-50%
Why this matters: CD4+ T-cell help is the critical difference between transient CTL priming and durable immunological memory. Studies show that vaccine formulations generating both responses produce T-cells with higher TCF-1 expression (memory precursor marker) and lower TIM-3/LAG-3 co-expression (exhaustion markers).
Protocol 3: TCR-T Cell Therapy with Lymphodepletion and Cytokine Support
For ACT research, the standard protocol from NCI trials:
| Phase | Protocol | Rationale |
|---|---|---|
| Lymphodepletion | Cyclophosphamide 60 mg/kg/day × 2 days + fludarabine 25 mg/m² × 5 days | Depletes Tregs; creates "space" for transferred T-cells; upregulates homeostatic cytokines |
| T-cell infusion | 2×10^9 – 2×10^10 1G4 TCR-T cells IV | Delivers NY-ESO-1-specific effectors |
| IL-2 support | 720,000 IU/kg IV q8h (up to 15 doses) | Supports early T-cell expansion and survival |
| Monitoring | Tetramer staining at days 7, 14, 30 post-infusion | Tracks in vivo T-cell persistence |
---
Safety Deep Dive
Common Side Effects in Vaccine Trials
NY-ESO-1 157-165 peptide itself has an excellent direct safety profile — it's a short, naturally occurring human protein fragment. Side effects arise primarily from the adjuvants and delivery systems used alongside it.
With Montanide ISA-51 adjuvant:
Injection site reactions: Erythema, induration, and pain at injection site — extremely common (>80% of vaccinated patients in most trials). Usually grade 1-2.
Granuloma formation: Persistent nodules at injection site in 10-20% of patients with Montanide. Generally benign but occasionally require surgical drainage.
Systemic flu-like symptoms: Fever, fatigue, myalgia within 24-48 hours of injection — 20-40% of patients. Grade 1-2 in most cases.
With CpG oligonucleotide adjuvants:
Transient lymphopenia and elevated CRP common (>50% of patients)
Flu-like symptoms: more pronounced than with Montanide alone
Rarely: transient thrombocytopenia (grade 1)
Immune-related adverse events (irAEs):
Theoretically possible if NY-ESO-1 expression occurs in any normal tissue. Current evidence suggests expression is absent in all normal tissues except testes and placenta, making autoimmune toxicity unlikely.
No cases of vitiligo (unlike melanoma-associated antigens like MART-1/gp100) have been reported in NY-ESO-1 157-165 vaccine trials, consistent with its absence from normal melanocytes.
Rare and Theoretical Risks
Epitope spreading: A successful NY-ESO-1 CTL response can theoretically damage tumor cells, releasing additional tumor antigens and triggering responses to non-targeted self-antigens. This is generally considered beneficial (it broadens anti-tumor immunity) but could theoretically contribute to irAEs if self-antigens are involved.
Cytokine release syndrome (CRS): Not reported with peptide vaccination. Relevant for TCR-T cell and CAR-T approaches, where large numbers of activated T-cells can release IL-6, IFN-γ, and TNF-α simultaneously. Grade 3-4 CRS was observed in approximately 10-15% of patients in the Robbins TCR-T cell trials, manageable with tocilizumab (anti-IL-6R).
Neurotoxicity: Reported with CAR-T cell therapies generally; not specifically associated with NY-ESO-1 targeting. The 1G4 TCR-T cell trials have not reported significant neurotoxicity, likely because NY-ESO-1 is not expressed in neural tissue.
Off-target TCR cross-reactivity: High-affinity engineered TCRs (like the 1G4 TCR) carry theoretical risk of recognizing unintended peptide-HLA combinations. The 1G4 TCR has been extensively screened against peptide libraries; no clinically significant cross-reactivity has been identified. However, this risk is why TCR affinity must be carefully optimized — too high affinity can paradoxically increase off-target risk.
Contraindications for Research Use
HLA-A*0201 negative subjects: The 157-165 peptide will not generate CTL responses in non-HLA-A*0201 individuals. HLA typing is a prerequisite for any research using this peptide.
Active autoimmune disease: Contraindication for vaccine approaches; could be exacerbated by adjuvant-driven immune activation.
Active infection: TLR-agonist adjuvants can exacerbate inflammatory states.
Pregnancy: NY-ESO-1 is expressed in placenta; theoretical risk of immune-mediated placental damage.
---
Compared to Alternatives: Where NY-ESO-1 157-165 Sits in the Cancer Immunotherapy Toolkit
| Feature | NY-ESO-1 157-165 | MART-1 27-35 | WT-1 126-134 | Survivin 96-104 |
|---|---|---|---|---|
| Antigen type | Cancer-testis antigen | Differentiation antigen | Overexpressed self-antigen | Overexpressed self-antigen |
| HLA restriction | HLA-A*0201 | HLA-A*0201 | HLA-A*0201 | HLA-A*0201 |
| Tumor expression | 20-80% (type-dependent) | 80-90% melanoma | 70-80% leukemias | 70-90% most cancers |
| Normal tissue expression | Testis only | Melanocytes, retina | Low-level various | Low-level various |
| Autoimmune risk | Very low | Moderate (vitiligo) | Low-moderate | Low |
| CTL response rate (vaccine) | 50-80% | 60-75% | 30-50% | 20-40% |
| Clinical response rate (ACT) | 45-67% (sarcoma) | 15-30% (melanoma) | 20-35% (AML) | Limited data |
| Spontaneous immunity | Yes (10-15% patients) | Rare | Rare | Rare |
| Cost tier (research grade) | $$ | $$ | $$ | $ |
| TCR engineering suitability | Excellent (1G4 TCR) | Good | Good | Limited |
| Best tumor type | Sarcoma, melanoma, ovarian | Melanoma | Leukemia, lung | Broad but weak |
MART-1 27-35 (sequence AAGIGILTV) is the main competitor in melanoma immunotherapy research. It has higher expression in melanoma but causes vitiligo in 20-30% of treated patients due to cross-reactivity with normal melanocytes. NY-ESO-1 157-165 has a cleaner safety profile in this regard.
WT-1 126-134 (Wilms Tumor 1 antigen) is particularly relevant for hematological malignancies. It's expressed in normal bone marrow progenitors at low levels, creating a narrow therapeutic window. NY-ESO-1 157-165 has a cleaner target tissue profile.
Survivin 96-104 targets a near-universal cancer antigen but the T-cell responses generated are typically low-magnitude, possibly due to central tolerance mechanisms. NY-ESO-1 157-165 benefits from the immune privilege of its normal expression site — the testes — meaning the immune system has not been tolerized to it.
---
What's Coming Next: The Research Frontier
NY-ESO-1 157-165 sits at the intersection of several of the most active areas in oncology research. Here's what the next five years will determine.
mRNA Vaccine Platforms
The COVID-19 mRNA vaccine revolution has directly accelerated NY-ESO-1 cancer vaccine development. Rather than delivering the peptide directly, mRNA vaccines encode the full NY-ESO-1 protein (or optimized epitope-focused sequences) and allow cells to produce the antigen endogenously, mimicking natural antigen processing. BioNTech's BNT111 is a lipid nanoparticle mRNA vaccine encoding four melanoma antigens including NY-ESO-1 epitopes. Phase II results (2023) showed mPFS of 8.5 months in pembrolizumab-combination arm vs. 4.5 months with pembrolizumab alone in advanced melanoma. Full Phase III data are expected by 2025-2026.
The key question: does mRNA delivery generate higher-quality T-cell responses (better memory formation, less exhaustion) compared to direct peptide vaccination? Early data from the BNT111 trial suggests yes, with higher TCF1+/PD-1+ progenitor exhausted T-cells (the cells that respond best to checkpoint blockade) in the mRNA arm.
Next-Generation TCR Engineering
The 1G4 TCR has been the workhorse of NY-ESO-1 TCR-T research, but its ~26 nM affinity, while high by natural standards, is still below the picomolar affinities achievable with protein engineering. Affinity-matured TCR variants with 10-100x higher affinity for NY-ESO-1 157-165/HLA-A*0201 are in preclinical development. The challenge: as affinity increases, off-target cross-reactivity risk increases non-linearly. The optimal affinity window appears to be 10-100 pM — enough to kill tumor cells at low antigen density, but not so high that normal peptide-HLA complexes trigger activation.
TCR bispecific antibodies (TCR-Bispecifics or ImmTACs) are a related approach from Immunocore. Tebentafusp (IMCgp100) is already FDA-approved for uveal melanoma, targeting gp100/HLA-A*0201. An ImmTAC targeting NY-ESO-1 157-165/HLA-A*0201 (IMCnyeso) is in Phase I trials. These molecules have a soluble, affinity-matured TCR fused to an anti-CD3 scFv — they redirect any T-cell (not just NY-ESO-1-specific ones) to kill NY-ESO-1-expressing tumor cells.
Combination with Epigenetic Priming
NY-ESO-1 expression in tumor cells is regulated by DNA methylation — the CTAG1B promoter is heavily methylated in NY-ESO-1-negative tumors. DNA methyltransferase inhibitors (5-azacytidine, decitabine) can demethylate this promoter and induce NY-ESO-1 expression in previously negative tumors. This creates a potential two-step strategy: first treat with epigenetic priming to expand the patient population, then apply NY-ESO-1 157-165-targeted immunotherapy.
A 2018 study in *Cancer Immunology Research* (Fonsatti et al.) showed that 5-azacytidine pretreatment induced NY-ESO-1 expression in 60% of previously NY-ESO-1-negative NSCLC cell lines and enhanced CTL-mediated killing by NY-ESO-1-specific T-cells by 3-8 fold.
Tumor-Infiltrating Lymphocyte Expansion
Some patients already have NY-ESO-1 157-165-specific T-cells present in their tumors — they've just been exhausted or suppressed. TIL therapy (like Iovance's lifileucel, FDA-approved 2024 for melanoma) expands all TILs including NY-ESO-1-specific ones. Next-generation approaches will use tetramer sorting to selectively expand NY-ESO-1 157-165-specific TILs from tumor biopsies, then engineer them with enhanced persistence and anti-exhaustion properties before reinfusion.
Unanswered Questions That Will Define the Next Decade
1. What is the minimum CTL frequency needed for tumor control? Current data suggest >0.5% tetramer-positive CD8+ T-cells in peripheral blood correlates with responses, but the threshold within the tumor microenvironment is unknown.
2. Can NY-ESO-1 157-165 vaccination prevent disease recurrence in the adjuvant setting? Most trials to date have treated metastatic disease. A trial in high-risk stage II-III melanoma patients after resection, where tumor burden is minimal, has never been completed with modern adjuvants.
3. How does HLA-A*0201 allele subtype affect response? HLA-A*02 has multiple subtypes (A*0201, A*0202, A*0203, etc.) with slightly different peptide-binding grooves. Most trials require A*0201 specifically, but whether A*0202 or A*0205 patients could benefit with modified peptides remains unexplored.
4. What is the optimal priming-boosting interval? Most trials use 2-4 week intervals, but immunological memory consolidation follows different kinetics. Studies using longer intervals (8-12 weeks) for boosting — mimicking the approach used in viral vaccines — have not been systematically tested.
---
Sourcing NY-ESO-1 157-165 for Research
NY-ESO-1 157-165 is available from multiple peptide synthesis vendors as a research-grade compound. When evaluating suppliers, researchers should require:
HPLC purity ≥ 95%: (98% preferred for in vivo use)
Mass spectrometry confirmation: of molecular weight (expected: ~1,052 Da for SLLMWITQC)
Endotoxin testing: (< 1 EU/mg for in vitro use; < 0.1 EU/mg for in vivo use)
Certificate of Analysis (CoA): with batch-specific data
Oxidation state documentation: (monomer vs. dimer; reduced vs. oxidized)
The peptide should be supplied lyophilized under nitrogen or argon atmosphere. Vendors offering custom synthesis can also provide the Cys→Ala variant (SLLMWITQA) or fluorescently labeled versions (FITC-SLLMWITQC) for specific research applications.
For HLA-A*0201/NY-ESO-1 157-165 tetramers, the standard source has been the NIH Tetramer Core Facility (free for academic researchers) and commercial vendors including MBL International, ProImmune, and BeckmanCoulter. Tetramers typically come as PE or APC conjugates at 0.5-1 mg/mL.
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.
---
Key Takeaways
NY-ESO-1 157-165 (SLLMWITQC): is a nine-amino-acid epitope from the NY-ESO-1 cancer-testis antigen, restricted to HLA-A*0201 — the most common HLA allele in Western populations.
The peptide binds HLA-A*0201 with an IC50 of 1-10 nM, placing it among the highest-affinity natural T-cell epitopes known, which is why it generates robust CTL responses.
NY-ESO-1 is expressed in 20-80% of solid tumors (highest in synovial sarcoma, ovarian cancer, and melanoma) but only in testis and placenta in normal tissue — giving it an excellent safety profile for targeted immunotherapy.
Peptide vaccination: with Montanide or CpG adjuvants generates tetramer-positive CD8+ T-cell frequencies of 0.5-3% in peripheral blood in 50-80% of HLA-A*0201+ vaccinated patients.
The 1G4 TCR-T cell therapy approach achieved a 67% objective response rate in synovial sarcoma — a tumor type with essentially no other systemic options — in the landmark Robbins et al. 2011 trial.
Combination with PD-1/PD-L1 checkpoint blockade: is the current standard approach in trials, preventing exhaustion of vaccine-primed CTLs.
The free cysteine at position 9 makes this peptide susceptible to oxidative dimerization; researchers must verify and control oxidation state for reproducible results.
mRNA vaccine platforms: encoding NY-ESO-1 epitopes (BNT111) have shown preliminary superiority over direct peptide vaccination in Phase II melanoma trials, with Phase III data expected by 2026.
DNA methyltransferase inhibitors: can expand the NY-ESO-1-positive patient population by epigenetically reactivating CTAG1B expression in previously negative tumors.
The biggest remaining question isn't whether NY-ESO-1 157-165-targeted therapy works — it clearly does in the right patients — but how to identify which patients will respond and how to combine approaches for maximal durability.
---